CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia

Leukemia and Lymphoma

Volumn 56, Issue 3, 2015, Pages 820-822

  Shen, Hongjie ^a   Chao, Hongying ^b   Ding, Zixuan ^a   Feng, Yufeng ^a   Cen, Jiannong ^a   Pan, Jinlan ^a   He, Jun ^a   Zhou, Ming ^b   Chen, Zixing ^a   Chen, Suning ^a  

^a SOOCHOW UNIVERSITY   (China)

^b THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN, HUMAN; CALRETICULIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; REPRESSOR PROTEIN; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; THROMBOCYTHEMIA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 84924745425     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.939963     Document Type: Letter

References (13)

1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
3. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544-1551.
4. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-1555.
5. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472-1477.
6. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28:1494-1500.
7. Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014 May 5. [Epub ahead of print]
8. Yan L, Ping N, Zhu M, et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 2012;97:1708-1712.
9. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011;96:607-611.
10. Eder-Azanza L, Navarro D, Aranaz P, et al. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. Leukemia 2014 Jun 12. [Epub ahead of print]
11. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis:differences in phenotype and prognostic impact. Leukemia 2014;28:1568-1570.
12. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014 Apr 19. [Epub ahead of print]
13. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012;51:743-755.